Deprescribing Medications Among Older Adults From End of Hospitalization Through Postacute Care: A Shed-MEDS Randomized Clinical Trial.

Eduard E Vasilevskis, Avantika Saraf Shah, Emily Kay Hollingsworth, Matthew Stephen Shotwell, Sunil Kripalani, Amanda S Mixon, Sandra F Simmons
Author Information
  1. Eduard E Vasilevskis: Center for Quality Aging, Vanderbilt University Medical Center, Nashville, Tennessee.
  2. Avantika Saraf Shah: Center for Quality Aging, Vanderbilt University Medical Center, Nashville, Tennessee.
  3. Emily Kay Hollingsworth: Center for Quality Aging, Vanderbilt University Medical Center, Nashville, Tennessee.
  4. Matthew Stephen Shotwell: Department of Biostatistics, Vanderbilt University, Nashville, Tennessee.
  5. Sunil Kripalani: Center for Quality Aging, Vanderbilt University Medical Center, Nashville, Tennessee.
  6. Amanda S Mixon: Center for Quality Aging, Vanderbilt University Medical Center, Nashville, Tennessee.
  7. Sandra F Simmons: Center for Quality Aging, Vanderbilt University Medical Center, Nashville, Tennessee.

Abstract

Importance: Deprescribing is a promising approach to addressing the burden of polypharmacy. Few studies have initiated comprehensive deprescribing in the hospital setting among older patients requiring ongoing care in a postacute care (PAC) facility.
Objective: To evaluate the efficacy of a patient-centered deprescribing intervention among hospitalized older adults transitioning or being discharged to a PAC facility.
Design, Setting, and Participants: This randomized clinical trial of the Shed-MEDS (Best Possible Medication History, Evaluate, Deprescribing Recommendations, and Synthesis) deprescribing intervention was conducted between March 2016 and October 2020. patients who were admitted to an academic medical center and discharged to 1 of 22 PAC facilities affiliated with the medical center were recruited. patients who were 50 years or older and had 5 or more prehospital medications were enrolled and randomized 1:1 to the intervention group or control group. patients who were non-English speaking, were unhoused, were long-stay residents of nursing homes, or had less than 6 months of life expectancy were excluded. An intention-to-treat approach was used.
Interventions: The intervention group received the Shed-MEDS intervention, which consisted of a pharmacist- or nurse practitioner-led comprehensive medication review, patient or surrogate-approved deprescribing recommendations, and deprescribing actions that were initiated in the hospital and continued throughout the PAC facility stay. The control group received usual care at the hospital and PAC facility.
Main Outcomes and Measures: The primary outcome was the total medication count at hospital discharge and PAC facility discharge, with follow-up assessments during the 90-day period after PAC facility discharge. Secondary outcomes included the total number of potentially inappropriate medications at each time point, the Drug Burden Index, and adverse events.
Results: A total of 372 Participants (mean [SD] age, 76.2 [10.7] years; 229 females [62%]) were randomized to the intervention or control groups. Of these Participants, 284 were included in the intention-to-treat analysis (142 in the intervention group and 142 in the control group). Overall, there was a statistically significant treatment effect, with patients in the intervention group taking a mean of 14% fewer medications at PAC facility discharge (mean ratio, 0.86; 95% CI, 0.80-0.93; P < .001) and 15% fewer medications at the 90-day follow-up (mean ratio, 0.85; 95% CI, 0.78-0.92; P < .001) compared with the control group. The intervention additionally reduced patient exposure to potentially inappropriate medications and Drug Burden Index. Adverse drug event rates were similar between the intervention and control groups (hazard ratio, 0.83; 95% CI, 0.52-1.30).
Conclusions and Relevance: Results of this trial showed that the Shed-MEDS patient-centered deprescribing intervention was safe and effective in reducing the total medication burden at PAC facility discharge and 90 days after discharge. Future studies are needed to examine the effect of this intervention on patient-reported and long-term clinical outcomes.
Trial Registration: ClinicalTrials.gov Identifier: NCT02979353.

Associated Data

ClinicalTrials.gov | NCT02979353

References

  1. J Biomed Inform. 2009 Apr;42(2):377-81 [PMID: 18929686]
  2. Br J Gen Pract. 2016 Aug;66(649):e552-60 [PMID: 27266865]
  3. J Am Geriatr Soc. 2022 Apr;70(4):1180-1189 [PMID: 34967444]
  4. Eur J Intern Med. 2017 Jul;42:e22-e23 [PMID: 28427802]
  5. Arch Intern Med. 2007 Apr 23;167(8):781-7 [PMID: 17452540]
  6. BMC Health Serv Res. 2015 Jul 23;15:282 [PMID: 26202163]
  7. BMC Health Serv Res. 2019 Mar 14;19(1):165 [PMID: 30871561]
  8. J Gerontol A Biol Sci Med Sci. 2022 May 5;77(5):1020-1034 [PMID: 34390339]
  9. Br J Clin Pharmacol. 2016 Sep;82(3):583-623 [PMID: 27077231]
  10. JAMA Intern Med. 2018 Jan 1;178(1):28-36 [PMID: 29131895]
  11. Eur J Hosp Pharm. 2017 Jan;24(1):10-15 [PMID: 28184303]
  12. Age Ageing. 2008 Nov;37(6):673-9 [PMID: 18829684]
  13. JAMA Intern Med. 2018 Dec 1;178(12):1673-1680 [PMID: 30326004]
  14. JAMA Netw Open. 2020 Mar 2;3(3):e201511 [PMID: 32207832]
  15. Drugs Aging. 2018 Apr;35(4):303-319 [PMID: 29541966]
  16. Intern Med J. 2016 Jan;46(1):35-42 [PMID: 26387783]
  17. Clin Pharmacol Ther. 1981 Aug;30(2):239-45 [PMID: 7249508]
  18. J Am Geriatr Soc. 2019 Dec;67(12):2482-2489 [PMID: 31648378]
  19. Age Ageing. 2019 Dec 1;49(1):102-110 [PMID: 31711097]
  20. J Gen Intern Med. 2016 Feb;31(2):196-202 [PMID: 26369941]
  21. Arch Intern Med. 1997 Oct 27;157(19):2205-10 [PMID: 9342997]
  22. Br J Clin Pharmacol. 2016 Aug;82(2):532-48 [PMID: 27059768]
  23. Ann Intern Med. 2017 Mar 21;166(6):419-429 [PMID: 28114673]
  24. J Am Geriatr Soc. 2019 Sep;67(9):1843-1850 [PMID: 31250427]
  25. BMJ. 2021 Jul 13;374:n1585 [PMID: 34257088]
  26. J Hosp Med. 2016 Oct;11(10):694-700 [PMID: 27255830]
  27. J Gen Intern Med. 2010 Feb;25(2):141-6 [PMID: 19967465]
  28. J Am Med Dir Assoc. 2012 Sep;13(7):611-7 [PMID: 22796362]
  29. J Chronic Dis. 1987;40(5):373-83 [PMID: 3558716]
  30. J Am Geriatr Soc. 2020 Mar;68(3):496-504 [PMID: 31840813]
  31. J Am Geriatr Soc. 2012 Apr;60(4):616-31 [PMID: 22376048]
  32. Int J Clin Pharm. 2019 Feb;41(1):159-166 [PMID: 30478496]
  33. Drugs Aging. 2008;25(12):1021-31 [PMID: 19021301]
  34. J Appl Gerontol. 2022 Mar;41(3):788-797 [PMID: 35164584]
  35. Gerontologist. 2022 Jul 26;: [PMID: 35881109]
  36. Ther Adv Drug Saf. 2018 Jun 15;9(9):523-533 [PMID: 30181860]
  37. Int J Clin Pharm. 2018 Oct;40(5):991-996 [PMID: 29926257]
  38. Australas J Ageing. 2019 Sep;38(3):206-210 [PMID: 30868694]
  39. Arch Intern Med. 2010 Oct 11;170(18):1648-54 [PMID: 20937924]
  40. Stat Med. 2019 Sep 30;38(22):4348-4362 [PMID: 31290191]
  41. JAMA Intern Med. 2022 May 1;182(5):534-542 [PMID: 35343999]
  42. JAMA Intern Med. 2019 Nov 01;179(11):1528-1536 [PMID: 31424475]
  43. J Am Geriatr Soc. 2019 Oct;67(10):2058-2064 [PMID: 31328791]

Grants

  1. R01 AG053264/NIA NIH HHS
  2. UL1 TR000445/NCATS NIH HHS

MeSH Term

Female
Humans
Aged
Deprescriptions
Subacute Care
Hospitalization
Patient Discharge
Potentially Inappropriate Medication List
Polypharmacy

Word Cloud

Created with Highcharts 10.0.0interventionPACfacilitygroupdeprescribingcontroldischarge0medicationshospitalShed-MEDStotalmeanDeprescribingoldercarerandomizedPatientsmedicationratio95%CIapproachburdenstudiesinitiatedcomprehensiveamongpatientspatient-centereddischargedclinicaltrialmedicalcenteryearsintention-to-treatreceivedpatientfollow-up90-dayoutcomesincludedpotentiallyinappropriateDrugBurdenIndexparticipantsgroups142effectfewerP <001Importance:promisingaddressingpolypharmacysettingrequiringongoingpostacuteObjective:evaluateefficacyhospitalizedadultstransitioningDesignSettingParticipants:BestPossibleMedicationHistoryEvaluateRecommendationsSynthesisconductedMarch2016October2020admittedacademic122facilitiesaffiliatedrecruited505prehospitalenrolled1:1non-Englishspeakingunhousedlong-stayresidentsnursinghomesless6monthslifeexpectancyexcludedusedInterventions:consistedpharmacist-nursepractitioner-ledreviewsurrogate-approvedrecommendationsactionscontinuedthroughoutstayusualMainOutcomesMeasures:primaryoutcomecountassessmentsperiodSecondarynumbertimepointadverseeventsResults:372[SD]age762[107]229females[62%]284analysisOverallstatisticallysignificanttreatmenttaking14%8680-09315%8578-092comparedadditionallyreducedexposureAdversedrugeventratessimilarhazard8352-130ConclusionsRelevance:Resultsshowedsafeeffectivereducing90daysFutureneededexaminepatient-reportedlong-termTrialRegistration:ClinicalTrialsgovIdentifier:NCT02979353MedicationsAmongOlderAdultsEndHospitalizationPostacuteCare:RandomizedClinicalTrial

Similar Articles

Cited By (23)